Enanta Pharmaceuticals (ENTA) Short-term Investments (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Short-term Investments data on file, last reported at $128.8 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments fell 3.24% year-over-year to $128.8 million; the trailing twelve-month figure through Mar 2026 stood at $128.8 million (down 3.24% YoY), and the FY2025 full-year result was $156.6 million, down 25.78% from the prior year.
• Short-term Investments for Q1 2026 stood at $128.8 million, down from $148.4 million in the prior quarter.
• Across five years, Short-term Investments topped out at $297.2 million in Q4 2023 and bottomed at $128.8 million in Q1 2026.
• The 5-year median for Short-term Investments is $183.3 million (2022), against an average of $191.7 million.
• Peak annual rise in Short-term Investments reached 72.94% in 2024, while the deepest fall reached 55.47% in 2024.
• A 5-year view of Short-term Investments shows it stood at $172.2 million in 2022, then jumped by 72.55% to $297.2 million in 2023, then plunged by 55.47% to $132.3 million in 2024, then gained by 12.14% to $148.4 million in 2025, then decreased by 13.18% to $128.8 million in 2026.
• The last three Short-term Investments figures came in at $128.8 million (Q1 2026), $148.4 million (Q4 2025), and $156.6 million (Q3 2025), per Business Quant data.

Peer Comparison